Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 10/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.79 |
| ▸ | TNF | P01375 | 1/20 | 0.79 |
| ▸ | MMP2 | P08253 | 1/20 | 0.79 |
| ▸ | MMP3 | P08254 | 1/20 | 0.79 |
| ▸ | MMP9 | P14780 | 1/20 | 0.79 |
| ▸ | MMP8 | P22894 | 1/20 | 0.79 |
| ▸ | MMP13 | P45452 | 1/20 | 0.79 |
| ▸ | MMP14 | P50281 | 1/20 | 0.79 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.79 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5892767 | 1.00 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892683 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892681 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892954 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892700 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL136238 | 0.89 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL26484 | 0.89 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL136239 | 0.89 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892613 | 0.88 | MMP1 (1.00) | MMP1ADAM17 | |
| SCHEMBL5892616 | 0.88 | MMP1 (1.00) | MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1081137-A1 | Selective inhibitors of aggrecanase in osteoarthritis treatment | Pfizer Products Inc. (US) | 2001-03-07 | — | — | EP | claimed |
| US-7030242-B2 | Selective inhibition of aggrecanase in osteoarthritis treatment | PFIZER INC (US) | 2006-04-18 | — | — | US | disclosed |
| US-20050227997-A1 | 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction | NOE MARK C | 2005-10-13 | — | — | US | disclosed |
| EP-1081137-A1 | Selective inhibitors of aggrecanase in osteoarthritis treatment | Pfizer Products Inc. (US) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227997-A1 | 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction | MMP3, MMP1, MMP13 | MMP1 2/4885ADAM17 18/4885ADAMTS4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.